You would think a company that just settled a multibillion-dollar lawsuit would be interested in going out on a limb, but Merck's
Earnings per share, excluding extras, are expected to be in the $3.08 to $3.14 range for 2007 and $3.28 to $3.38 for 2008. Using the middle of the ranges for both years, that's a decent, but certainly not stellar, 7% growth rate.
This time last year, the company was projecting non-GAAP earnings per share in 2007 between $2.51 and $2.59. It looks as though it should blow that projection out of the water, so it's probably a decent guess that the company is also being conservative with its 2008 estimate.
It's not as if Merck won't have issues in 2008. The company will lose patent protection on three drugs, including Fosamax -- its second best seller in the U.S. But expanding sales of its human papillomavirus vaccine GARDASIL, diabetes drugs JANUVIA and JANUMET, and HIV drug ISENTRESS should make up for the lost revenues from generic competition.
Merck's vaccine sales will see a slowdown after a banner 2007, where global sales are expected to more than double. In 2008, Merck is expecting just a 14% increase in global sales as GARDASIL runs into competition from GlaxoSmithKline's
Revenue from its equity partnerships with the likes of AstraZeneca
Only time will tell whether Merck is being cautious or not, but given its previous track record, I think it's safe not to put too much faith in its estimates.
Glaxo, Merck, and Johnson & Johnson are all picks of the Income Investor newsletter. If you'd like to see more ideas for stocks that pay dividends, grab a 30-day free trial of the newsletter and check all of our past recommendations.